Donanemab is a medicine designed by Eli Lilly for the treatment of Alzheimer’s. In a May 2023 announcement, the company said that it found in trials that Donanemab slowed the decline in the ability of Alzheimer’s patients to perform daily tasks and think clearly.
Donanemab News Timeline
Study Finds Donanemab Helps Alzheimer’s Patients. “The medicine, donanemab, works by removing plaque buildups in the brain known as amyloid that are a hallmark of Alzheimer’s disease. However, there were some side effects reported; there were three deaths in the trial among people taking the drug, two of which were attributed to adverse events such as brain swelling or microhemorrhages, known as amyloid-related imaging abnormalities or ARIA. The trial was run in more than 1,700 patients for 18 months. “For every medicine, for every disease, there are potential risks and potential benefits,” said Lilly’s chief scientific and medical officer, Dr. Daniel Skovronsky. But he noted that almost half of the participants taking the drug, 47%, showed no decline on a key measure of cognition over the course of a year, compared with 29% of people taking a placebo.” [MORE]
Eli Lilly Stock Value Rose After Donanemab News. “Shares of the Illinois-based drugmaker Eli Lilly (NYSE: LLY) were up by 6% on heavy volume as of 1:45 p.m. ET Wednesday. What sparked this latest rally? Ahead of the opening bell, Lilly announced that its early-stage Alzheimer’s disease treatment, donanemab, slowed cognitive decline by a clinically meaningful 35% in a late-stage trial.” [MORE]
One of the first political bloggers in the world, Oliver Willis has operated OliverWillis.com since 2000. Contributor at Media Matters for America and The American Independent. Follow on Twitter at @owillis. Full bio.